Infant Bacterial Therapeutics AB (OSTO:IBT B) Cash per Share : kr14.24 (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Infant Bacterial Therapeutics AB's Cash per Share for the quarter that ended in Mar. 2025 was kr14.24.

Infant Bacterial Therapeutics AB Cash per Share Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Cash per Share Chart

Infant Bacterial Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash per Share

Get a 7-Day Free Trial

37.72

34.45

29.92

24.43

16.58

Infant Bacterial Therapeutics AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash per Share	Get a 7-Day Free Trial															22.98	20.23	16.79	16.58	14.24

Infant Bacterial Therapeutics AB Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Infant Bacterial Therapeutics AB's Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	223.388	/	13.47
	=	16.58

Infant Bacterial Therapeutics AB's Cash per Share for the quarter that ended in Mar. 2025 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	191.758	/	13.47
	=	14.23

Infant Bacterial Therapeutics AB (OSTO:IBT B) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Infant Bacterial Therapeutics AB Cash per Share Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Infant Bacterial Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

9IB:Germany

Address

Bryggargatan 10, Stockholm, SWE, 111 21

Website

https://www.ibtherapeutics.com

Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines